Retraction Notice

Title of retracted article: The Results Observation on Adjuvant Chemotherapy with Microwave Hyperthermia and Stereotactic Radiotherapy in Retreated Elderly Patients with Advanced (III/IV Stage) Lung Cancer

Author(s): Xihao Yu 1, Xinping Li 1, Guiyun Dong 1, Wenyan Yu 2, Jianping Wang 1, Ying Xiong 1

* Corresponding author. Email: yuxih@tom.com

Journal: Journal of Computer and Communications (JCC)
Year: 2016
Volume: 4
Number: 3
Pages (from - to): 79 - 82
DOI (to PDF): 10.4236/jcc.2016.43012
Paper ID at SCIRP: 64147
Retraction date: 2016-03-21

Retraction initiative (multiple responses allowed; mark with X):
☐ All authors
☐ Some of the authors:
☐ Editor with hints from
☐ Journal owner (publisher)
☐ Institution:
☐ Reader:
☐ Other:

Date initiative is launched: 2016-03-21

Retraction type (multiple responses allowed):
☐ Unreliable findings
☐ Lab error
☐ Inconsistent data
☐ Analytical error
☐ Biased interpretation
☐ Other:
☐ Irreproducible results
☐ Failure to disclose a major competing interest likely to influence interpretations or recommendations
☐ Unethical research
☐ Fraud
☐ Data fabrication
☐ Fake publication
☐ Other:
☐ Plagiarism
☐ Self plagiarism
☐ Overlap
☐ Redundant publication *
☐ Copyright infringement
☐ Other legal concern:
☐ Other legal concern:
☐ Other:

☐ Other:
Publish in inappropriate journal

Results of publication (only one response allowed):
☐ are still valid.
☒ were found to be overall invalid.

Author’s conduct (only one response allowed):
☐ honest error
☐ academic misconduct
☒ none (not applicable in this case – e.g. in case of editorial reasons)

* Also called duplicate or repetitive publication. Definition: "Publishing or attempting to publish substantially the same work more than once."
History
Expression of Concern:
☐ yes, date: yyyy-mm-dd
☒ no

Correction:
☐ yes, date: yyyy-mm-dd
☒ no

Comment:
Free style text with summary of information from above and more details that can not be expressed by ticking boxes.

This article has been retracted to straighten the academic record. In making this decision the Editorial Board follows COPE’s Retraction Guidelines. Aim is to promote the circulation of scientific research by offering an ideal research publication platform with due consideration of internationally accepted standards on publication ethics. The Editorial Board would like to extend its sincere apologies for any inconvenience this retraction may have caused.

Editor guiding this retraction:  
Firstname Lastname  
(function e.g. EiC, journal abbreviation)

Instructions for Further Editorial Changes to the Online Publication (to be deleted from final notice)

- On the article page...
  - ... the title is preceded by the text: RETRACTED:
  - ... the abstract is exchanged by ...
    - ... a heading: Short Retraction Notice
    - ... body text: The comment from above
    - ... a final text: The full retraction notice in PDF is preceding the original paper, which is marked "RETRACTED".
  - ... the reference under the heading Cite this paper is deleted.
  - ... the metadata in the HTML source code of the article page is only changed with respect to the abstract:
    - <meta name="description" content="...">
    - and <meta name="citation_abstract" content="...">
    - are set to the same new abstract as explained above and consist of:
      - the heading, the body text, a final text (without the link).

- The original article in PDF...
  - ... receives on each page a red watermark RETRACTED (running diagonally across each page in big letters),
  - ... is preceded with the Retraction Notice from these two pages (but without these instructions), which is showing on top the CrossMark logo with the link * set to the publication date of the retraction,
  - ... gets the link * under the CrossMark logo of the original article changed to the publication date of the retraction,

- The original article in HTML...
  - ... is replaced by the Short Retraction Notice copied from the article page.
  - ... has a final text: Please see the article page for more details.
    The full retraction notice in PDF is preceding the original paper, which is marked "RETRACTED".
  - ... the metadata in the HTML source code is changed as explained above.

- The XML of the original article is deleted.

* The link under the CrossMark logo follows the pattern:  
  http://crossmark.crossref.org/dialog/?doi=10.4236/...&domain=pdf&date_stamp=yyyy-mm-dd
  yyyy-mm-dd is the date (ISO 8601).
The Results Observation on Adjuvant Chemotherapy with Microwave Hyperthermia and Stereotactic Radiotherapy in Retreated Elderly Patients with Advanced (III/IV Stage) Lung Cancer

Xihao Yu¹, Xinping Li¹, Guiyun Dong¹, Wenyan Yu², Jianping Wang¹, Ying Xiong¹

¹Department of Oncology of Liberation Army 85 Hospital, Shanghai, China
²Basic Medical College of Shanghai Jiaotong University, Shanghai, China

Email: yuxih@tom.com

Received 14 January 2016; accepted 26 February 2016; published 2 March 2016

Abstract

Objective: To evaluate the significance of adjuvant chemotherapy and radiotherapy (Gamma-knife) in the elderly patients with retreating advanced lung cancer. Methods 83 patients (age 50 to 81 years) with retreating advanced (III/IV stage) lung cancer were divided into three groups according to the patients received treating by different methods. The cases were treated by synchronous chemo-radiotherapy (A group), sequentially chemo-radiotherapy (B group) and continuous systematized chemotherapy alone (C group). The systemic 3-dimensional orientation apparatus was used in radiotherapy. The chemotherapy regimen in combined radiotherapy was given by common first line regimen on lung cancer. The regimen of chemotherapy combated with whole body hyperthermia by using micro-wave on abodeman about 2 or 3 line was used in C group only. Results: The overall responses rates (RR) of A, B and C groups were 17.1%, 11.5% and 31.8%, but it was non-significance difference (P > 0.05). Overall responses rates (RR) of III and IV stage groups were 18.2% and 20.0%. The average overall survival time (OS) and median survival time (MST) of the patients treated by chemotherapy (C group) were highest about 14.2 and 9.3 months (respectively at A group 6.7 and 6.0 months. P < 0.01), in which B group was longer than A group (P < 0.05), and 95.5% CI value was not overlap. The total survival time of postoperative patients was longer in the various groups by different treated than that in non-operations. Conclusion: The rates (RR) of III and IV stage groups were non-significance difference. The higher of ORR, OS and MST in a few patients of re-treated advanced lung cancer was presented in case with treated by continuous system chemotherapy. There were survival superiority in initial postoperative patients groups by different treated. It is a profitable and effect treatment that the pure reasonable systemic chemotherapy was used for elderly case with advanced retreated lung cancer.

Keywords
Elderly Patients, Chemotherapy, Combined Radiotherapy, Lung Cancer

1. Background
The retreating to elder patients with advanced lung cancer is a problem that often needs to be faced in clinical practice. A number of studies have shown that appropriately chemotherapy or radiotherapy is better than the best supportive care. Due to the special physiological function of old patients, it was considered that how to choose the best treatment for the patients. Especially for patients treated again, at present this kind of research is not much. It is object about the paper to investigate the effect and significance of adjuvant chemotherapy with hyperthermia and radiotherapy (Gamma-knife) in the treatment of elderly patients with retreated advance lung cancer.

2. Clinical Material and Methods
Eighty-three patients, median age 67.3 year (50 to 81 years), with retreated advanced (III/IV stage) lung cancer were divided into three groups according to patients received treating by different methods. 35 cases were treated by synchronous chemo-radiotherapy (group A). 26 cases were treated by sequentially chemo-radiotherapy (group B) and 22 cases were treated by continuous systematized chemotherapy alone (group C). (see Table 1). All patients were selected for inclusion in study after the initial treatment stopped 2 - 3 months. The systemic 3-dimensional orientation apparatus was used in radiotherapy. The total dose of 35-55GY was given in synchronous or sequential chemo-radiotherapy. The chemotherapy regimen in combined radiotherapy was given by common first line regimen on lung cancer. (NSCLC: NVB25 mg/m² d1, 8, GEM 0.8 - 1.0/m² d1, 8, DDP 40 mg d1-3 or DDP20 mg d1-5. SCLC: CBP AUC = 5, VP16 0.1/m². q21d). The part chemotherapy combated with whole body hyperthermia by using micro-wave on abdomen in temperature 40°C - 42°C for 1 - 2 hours. The regimen of chemotherapy about 2 or 3 line was used in C group only. Drugs was used at Taxol (Squibb US, Co) 175 mg/m² d1, or Docertacel (Aventis Pharma, SA, Co) 70 - 80 mg/m², d1; Pemetrexed (Lilly France SAS, Co) 500 mg/m², d1.). The responce rate was statistically based on RECIST (WHO) method.

Statistical analysis The categorical variables percent date were compared between the two groups by using the independent X² test. Continuous data were compared between two groups by using independent t test. A two-tailed P value of < 0.05 was considered statistically significant. Survival was calculated by using the Kaplan-Meier method and compared by using the log-rank test. The Kaplan-meier curve was used to exhibit survival time.

3. Results
1) The overall responses rates (RR) of A, B and C groups were 17.1%, 11.5% and 31.8%, but it was non-significance difference respectively at three group (P > 0.05). The higher effective rate was presented in stage III case with synchronous chemo-radiotherapy (23.1%), and in stage IV with continuous systematized chemothera-phy alone (38.5%), but overall responses rates (RR) of III/IV stage groups was non-significance difference (18.2% and 20.0%) (see Table 2).

2) The average overall survival time (OS) and median survival time (MST) of the patients treated by chem-

Table 1. The general state of the patients with cancer on different treating groups.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Cases</th>
<th>SEX</th>
<th>Mid-age</th>
<th>Stage (%)</th>
<th>PS (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>M</td>
<td>F</td>
<td>III</td>
<td>IV</td>
</tr>
<tr>
<td>group A</td>
<td>35</td>
<td>23</td>
<td>12</td>
<td>54.6</td>
<td>13 (37.1)</td>
</tr>
<tr>
<td>group B</td>
<td>26</td>
<td>20</td>
<td>6</td>
<td>51.2</td>
<td>11 (42.3)</td>
</tr>
<tr>
<td>group C</td>
<td>22</td>
<td>13</td>
<td>9</td>
<td>56.5</td>
<td>9 (40.9)</td>
</tr>
</tbody>
</table>

¹P > 0.05.
therapy (C group) were highest about 14.2 and 9.3 months (respectively at A group 6.7 and 6.0 months. P < 0.01), in which B group was longer than A group (P < 0.05), and 95.5% CI value was not overlap. The Kaplan-meier curve for survival time was showed (shown in Figure 1).

3) The total survival time of initial postoperative patients were longer in the various groups by different treated than that in non-operations (see Table 3).

Table 2. The contrast about respond rate (RR) in different treating groups.

<table>
<thead>
<tr>
<th>Group</th>
<th>Stage III</th>
<th></th>
<th>Stage IV</th>
<th></th>
<th>RR (%)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>RR (%)</td>
<td>N</td>
<td>RR (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Syn.che-rad (A)</td>
<td>13</td>
<td>3 (23.1)</td>
<td>22</td>
<td>3 (13.6)</td>
<td>6/35</td>
<td>(17.1)</td>
</tr>
<tr>
<td>Seq.che-rad (B)</td>
<td>11</td>
<td>1 (9.1)</td>
<td>15</td>
<td>2 (13.3)</td>
<td>3/26</td>
<td>(11.5)</td>
</tr>
<tr>
<td>Chem.onl (C)</td>
<td>9</td>
<td>2 (22.2)</td>
<td>13</td>
<td>5 (38.5)</td>
<td>7/22</td>
<td>(33.6)</td>
</tr>
<tr>
<td></td>
<td>33</td>
<td>6 (18.2)</td>
<td>50</td>
<td>10 (20.0)</td>
<td>16/83</td>
<td>(19.3)</td>
</tr>
</tbody>
</table>

\* $X^2 = 1.87, P > 0.05$ (contrast between C and B); \^ $X^2 = 2.86, P > 0.05$ (contrast between C and A); \$ $X^2 = 0.51, P > 0.05$ (contrast between stage IV and III in A group).

Table 3. Survival time (months) on different treating groups with post-operation.

<table>
<thead>
<tr>
<th>Content</th>
<th>No operation</th>
<th></th>
<th>Post-operation</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>$\bar{X}$</td>
<td>MST</td>
<td>n</td>
</tr>
<tr>
<td>Syn.che-rad (A)</td>
<td>30</td>
<td>6.5</td>
<td>5.0</td>
<td>5</td>
</tr>
<tr>
<td>Seq.che-rad (B)</td>
<td>20</td>
<td>9.9</td>
<td>7.0</td>
<td>6</td>
</tr>
<tr>
<td>Chem.onl ©</td>
<td>17</td>
<td>9.9</td>
<td>9.0</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>65</td>
<td>9.0</td>
<td>7.0</td>
<td>16</td>
</tr>
</tbody>
</table>

\* $t = 2.79, P < 0.01$ (post-op.cont no ope. about MST).

Figure 1. The Kaplan-meier survival rate of different treating groups. –●: group A, –■: group B, –▲: group C.
4. Discussion

Stereotactic gamma knife radiotherapy for intracranial tumor and somatic localized tumors can make small part of radical effect to the operation as a knife. However, chemotherapy is often needed for patient with recurrence and metastasis [1]. However studies have indicated that, after radiotherapy or early chemotherapy, the residual tumor cells can accelerate the proliferation, which make the tumor more difficult to control [2]. So it is very important to follow up the system chemotherapy or consolidation chemotherapy. Hyperthermia can increase the efficacy of chemotherapy and reduce side effect, in which it can appropriately reduce the dose of chemotherapy drug and more suitable for the elderly. Although surgical treatment of lung cancer, especially in the initial treatment still occupies an important position [3], our research also shows that there were survival superiority in initial postoperative patients groups by subsequent different treated. But it is not possible for the elderly tumor patients to choose again. This clinical observation study of this paper suggested that the synchronous chemoradiotherapy can partly increased about RR of the patients with stage III case, and higher effective rate was presented in stage IV with continuous systematized chemotherapy, but the rates (RR) of III and IV stage groups were non-significance difference. The higher of ORR, OS and MST in a few patients of re-treated advanced lung cancer was presented in case with treated by continuous system chemotherapy. Conclusion: It is a profitable and effect treatment that the pure reasonable systemic chemotherapy was used for elderly case with advanced retreated lung cancer.

References

